FDA Tentatively Approves First Generic HIV-Prevention Shot

The first generic competitor to one of the most effective HIV-prevention tools ever approved has cleared FDA review. On November 2, 2026, FDA gave tentative approval to Dr. Reddy's Laboratories' generic version of injectable lenacapavir — a milestone that opens the door to a roughly $40-a-year version of a drug that, as a brand-name product, has listed at tens of thousands of dollars annually in the United States.

What tentative approval actually means

Tentative approval is a specific, narrower designation than a standard generic approval. It tells a sponsor that FDA has reviewed the application and found the product meets the agency's standards for quality, manufacturing and bioequivalence to the reference product — but that approval cannot take effect for U.S. marketing purposes while patents or exclusivity periods covering the brand-name product remain in force. Gilead's lenacapavir patents are not expiring in the near term; the mechanism that makes Dr. Reddy's generic usable now runs through the licensing agreements Gilead itself signed, not through patent expiry.

The licensing structure behind the price

In October 2024, Gilead signed royalty-free voluntary licensing agreements with six generic manufacturers — Dr. Reddy's, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero and Mylan, a Viatris subsidiary — covering 120 high-incidence, resource-limited countries. The agreements were signed ahead of any global regulatory submission, an unusually early move intended to let generic manufacturing start as close as possible to the originator's own approval. Dr. Reddy's is the first of the six to convert that license into an actual FDA tentative approval, which functions as the United States' quality-assurance checkpoint even for a product that will not be sold domestically.

Who made the case to FDA

Unitaid, the Clinton Health Access Initiative and Wits RHI (the Wits Reproductive Health and HIV Institute, part of the University of the Witwatersrand) backed Dr. Reddy's application with financial, technical and regulatory support. A specific structural choice sped the review: the partners combined lenacapavir's HIV-prevention and HIV-treatment indications into a single application rather than filing separately, which allowed Dr. Reddy's to request and receive priority review. Unitaid said more than 125,000 people across ten early-adopter African countries have already started on Gilead's own lenacapavir, ahead of generic availability — the population this approval is meant to serve at scale.

What happens next

• Supply bridge: Gilead has committed to supply its own product at no profit in the licensed countries until generic manufacturing can meet demand, through a coordinated partnership with PEPFAR and the Global Fund.
• Timeline: coverage of the announcement describes initial generic supplies reaching eligible countries by the end of 2026, with a broader rollout in 2027; Gilead's own public materials describe some licensees aiming to begin supply as early as 2027.
• Five licensees to go: Emcure, Eva Pharma, Ferozsons, Hetero and Mylan have the same royalty-free license but have not yet reached FDA tentative approval; each will need its own review.
• Coverage gaps: the 120-country license list does not include several middle-income countries with substantial HIV epidemics, including in Latin America — a gap Gilead says it is addressing through tiered pricing rather than the licensing program itself.

Frequently asked questions

What did FDA approve on November 2, 2026?

Tentative approval of Dr. Reddy's generic injectable lenacapavir for HIV prevention, roughly 16 months after FDA approved Gilead's brand-name originator, Yeztugo, in June 2025.

Why “tentative” and not full approval?

It confirms the generic meets FDA's quality, safety and bioequivalence standards while the brand-name product's U.S. patents and exclusivity remain in force; it does not permit U.S. sales.

Where can the generic be sold?

In the 120 countries covered by Gilead's October 2024 royalty-free voluntary licenses with six generic manufacturers; Dr. Reddy's is the first of the six to reach FDA tentative approval.

What role did Unitaid and partners play?

Unitaid, CHAI and Wits RHI backed the application and combined its prevention and treatment indications into one filing to secure priority review; the partners' agreement targets a price near $40 per person per year.

When will the generic reach patients?

Initial supplies are expected to reach eligible countries by the end of 2026, with broader rollout in 2027, while Gilead supplies its own product at no profit in the interim through its PEPFAR and Global Fund partnership.